FUSILEV is already approved in EUROPE, and was approved for another disease by FDA last year.
SO this means 99.9999999% approval!
With approval of Fusilev, they can increase their revenue from FUsilev by 2X!
Now Fusilev is selling $9mln per quarter. That's $36mln per quarter.
With this approval, there will be more target patients, and expect more than double revenue which is $72mln!
SPPI market cap is only $300mln now. Really low.
Zevalin sales may top $180mln, so we may see a target revenue of $250mln by 2010.
That will put SPPI in the league of the $250mln revenue medical stock. Which usually have market cap of 1bln or more.
So expect SPPI to have that market CAP and we will see 3X gains.
SPPI will be $20 by year end.
They still got eoquin. bladder cancer drug which is crazily expensive too!
BUY in today should not be wrong. The most u can trade this n sell at $9.
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM